Introduction
Chronic kidney disease (CKD), defined as a reduced estimated glomerular filtration rate (<60 ml/min/ 1.73 m 2 ), increased urinary albumin excretion (>30 mg/ g of creatinine), or both, is a substantial cause of morbidity and mortality worldwide, and a growing public health concern [1, 2] . The estimated global prevalence of CKD is 8-16% in the general population, rising to over 50% in high-risk subgroups [1, 3] ; however, few drugs for kidney disease have been successfully developed over the past 15 years [4] . While many therapeutic interventions have initially appeared effective in animal models, translation of these results into humans in the clinical setting has remained challenging [5] . There is a particularly high unmet medical need for new therapies in cases where guideline-recommended CKD treatments are unsuccessful. These patients are likely to have persistent high blood pressure and increased albumin excretion, which puts them at increased risk of rapid progression to endstage renal disease (ESRD) [6] [7] [8] .
Direct stimulation of soluble guanylate cyclase (sGC) is a novel therapeutic approach under investigation for various cardiovascular disorders associated with endothelial dysfunction. It has also been shown to have beneficial effects on renal tissue remodeling and organ function [9] . This review will focus on preclinical data on two classes of compounds that directly modulate sGC, sGC stimulators, and sGC activators. These compounds increase cyclic guanosine monophosphate (cGMP) formation under normal conditions and conditions where nitric oxide (NO) formation and bioavailability are impaired or NO tolerance has developed [10] . Given their non-overlapping mechanism of action compared with current therapies, activators and stimulators of sGC may offer an alternative option for patients who are unresponsive to available modalities and who therefore are at high risk of rapidly progressing to more serious disease.
Pathogenesis of CKD
Excessive accumulation of extracellular matrix occurs in virtually every type of CKD, leading to renal fibrosis [5] . Three key pathways have been identified in promoting tissue matrix expansion: firstly, elevated synthesis of extracellular matrix components; secondly, increased inhibition of matrix degradation; and finally, upregulated local expression of integrins [11] . This pathogenic process is progressive and ultimately leads to ESRD [5] . There are believed to be several pathways of progression toward ESRD at the cellular and molecular level; injury to the tubulointerstitium, the renal parenchyma comprising the tubules and bounded by the vasculature and nephrons, may be one of these pathways [12] .
NO and cGMP deficiency are implicated in the pathogenesis of multiple organ systems, including the cardiovascular system and importantly, the renal system [10] . NO deficiency has been documented in numerous experimental and human renal diseases, including hypertension and diabetic nephropathy, glomerulosclerosis, obstructive nephropathy, and chronic interstitial nephritis, as well as renal diseases due to cyclosporine A and radiocontrast media [13] [14] [15] [16] [17] [18] [19] [20] [21] .
Pharmacological blockade of NO has been utilized to study the effects of NO inhibition in animal models of renal disease. In a rat model of obstructive nephropathy, increased fibrosis and apoptosis, and reduced blood flow and filtration rates were observed with the use of the NO synthase inhibitor L-NAME as compared with control animals [13] . In another study in rats, increased arterial pressure and reduced renal blood flow were observed as a result of treatment with L-NAME. The hemodynamic effects induced by NO inhibition were normalized by sGC activation, demonstrating that the function of NO is mediated by the cGMP pathway [22] . Together, this research has demonstrated that NO and cGMP deficiency contribute to the progression of CKD through both hemodynamic and direct pro-fibrotic effects. It also reveals a protective role of NO on renal function, interstitial fibrosis, and renal tubular apoptosis [13] . More than 80% of patients with CKD are hypertensive [23] , and in most, if not all cases, the dominating pathohistological feature of their underlying kidney disorder is accumulation of extracellular matrix proteins [5] .
Due to the established link between NO deficiency and vascular pathophysiology, targeting of the NO signaling pathway has become a therapeutic strategy; for example, organic nitrates have been used to treat cardiovascular disease for more than 150 years [24] . However, resistance to NO, non-specific, and cytotoxic effects and other limitations associated with such treatments have led to an interest in targeting the sGC pathway directly, resulting in the discovery and development of sGC stimulators and activators [24] .
Soluble guanylate cyclase
The enzyme sGC is a heterodimeric complex composed of two subunits (a and b), and is responsible, across various species and systems, for catalyzing cGMP formation from guanosine triphosphate. The prosthetic heme moiety at the b-subunit of sGC is essential for NO binding and subsequent enzyme activation [10] . NO is produced in response to physiological stimuli such as shear stress, and induces relaxation in the cardiovascular system through its modulation of sGC and cGMP levels, and consequent regulation of vascular tone and blood pressure. Under conditions where NO formation and bioavailability are impaired or NO tolerance has been established, two classes of compounds have been developed that can directly modulate sGC and increase cGMP formation: sGC stimulators and sGC activators [10] .
Stimulators and activators of sGC target the enzyme in two different redox states: the NO-sensitive reduced (ferrous) enzyme and NO-insensitive oxidized (ferric) enzyme, and finally heme-free enzyme, respectively ( Figure 1 ). Stimulators of sGC stimulate the reduced form of sGC directly and synergize with NO by stabilizing the nitrosyl-heme complex of reduced sGC [24] . Conversely, sGC activators increase the activity of the enzyme only when the heme iron is oxidized which subsequently lead to the heme-free enzyme. They bind to the unoccupied heme-binding complex, and produce only an additive effect with NO. In certain cases, sGC activators also protect sGC from oxidation-induced proteasomal degradation [24] .
sGC stimulators
Effect of sGC stimulators in experimental kidney and cardiovascular disease
In 1994, scientists at Bayer started a screening for substances that could induce an increase in NO synthesis and thereby stimulate sGC in porcine endothelial cells. This screening led to the unexpected discovery of NO-independent sGC stimulators. At the same time it was reported that a benzyl indazole compound named YC-1 inhibited platelet aggregation by stimulation of cGMP synthesis. This compound was subsequently characterized as a direct NO-independent, but heme-dependent, sGC stimulator [10, 25] . Kidney fibrosis induced by unilateral ureter ligation was inhibited by YC-1 via activation of cGMP-dependent protein kinase I [26] . However, along with its relatively weak sGC stimulating potency, it revealed a poor pharmacokinetic profile and a lack of specificity, as it was found to inhibit phosphodiesterases and to modulate many cGMP-independent effects [27] . Therefore, further optimization of potency, pharmacokinetic properties, and specificity was required to realize the full therapeutic potential of this novel class of drugs [25] . Since YC-1, the sGC stimulators BAY 41-2272, BAY 41-8543, BAY 60-4552, riociguat, and vericiguat have been developed, and their effects have been investigated in experimental models of kidney and cardiovascular disease [9,28-41,42 ,43,44] . A summary of some of the results of these investigations is given below and in Table 1 and Figure 2 . Administration of BAY 41-2272 to rats with an acute form of glomerulonephritis attenuated renal dysfunction, as determined by significant reductions in proteinuria and systolic blood pressure (Figure 2a ) as compared with untreated and control animals [36] . This effect was accompanied by decreased transforming growth factor beta (TGFb) production, matrix deposition, and macrophage infiltration, which was found to occur independently of changes in blood pressure [36] . In another study, using the same model, BAY 41-2272 elevated cGMP levels in mesangial cells, thereby reducing their proliferation and matrix production compared with placebo-treated animals. Again, treated rats had significantly lower proteinuria levels than controls and the effects were found to have a direct pressure-independent component [30 ] . Furthermore, BAY 41-2272 was shown to significantly limit the course of chronic glomerulonephritis in a rat model [41] . Improvements in kidney function, as assessed by lower plasma creatinine and urea levels, were observed. A further study found that BAY 41-2272 protected the kidney from progressive sclerosis and matrix deposition by limiting TGFb expression [42 ] .
Both BAY 41-2272 and BAY 41-8543, when administered orally, produced dose-dependent vasodilation and markedly improved survival, compared with untreated controls, in rat models of hypertension, without causing tolerance [39, 40] . In aged spontaneously hypertensive rats, BAY 41-2272 rapidly reversed existing pathological cardiac changes, for example by decreasing fibrosis levels to those of age-matched normotensive rats [31] .
Studies in L-NAME-induced low-NO rat models of hypertension demonstrated that BAY 41-8543 had a renal protective effect (decreased plasma levels of urea and creatinine compared with untreated controls) [40] , while BAY 41-2272 attenuated cardiac fibrosis ( Figure 2b ) and hypertrophy [44] . In other studies, and at a dose below that affecting blood pressure, BAY 41-2272 nevertheless attenuated cardiac fibrosis in rodent models of hypertension induced by infusion of angiotensin II [33] or suprarenal aortic constriction [34] . These findings suggest that sGC stimulation may protect against organ injury independently of its effects on vascular tone.
Increased cGMP production and subsequently enhanced renal recovery after unilateral ureteral obstruction relief was observed with sGC stimulation by BAY 41-8543 in a rat model, compared with obstruction relief alone [43] . This suggests that BAY 41-8543 may serve as a novel treatment approach to restore or preserve renal structure and function in cases of obstructive kidney disease [45] .
BAY 60-4552
Limited published data are currently available for the other sGC stimulator, BAY 60-4552. However, in (Figure 2c ), attenuated the development of hypertrophy, reduced urine output and microalbuminuria, and attenuated increases in blood pressure compared with untreated controls [29] .
Riociguat
Riociguat (BAY 63-2521) is the most advanced of the sGC stimulators. It has been approved for use in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension [46, 47] , and is in clinical development for a number of other indications [48] . Riociguat is a heme-dependent sGC stimulator closely related to BAY 41-2272 and BAY 41-8543 [10] . In two independent rat models of hypertension, riociguat had a potent protective effect against cardiac and renal damage. In the first model (low-NO/high-renin), riociguat induced a marked dose-dependent decrease in renal interstitial fibrosis and normalized blood pressure versus control rats [38 ] . In a subtotal nephrectomy rat model, riociguat-treated rats exhibited significantly lower blood pressure compared with untreated sham-operated animals, and had a significantly higher creatinine clearance compared with untreated rats [38 ] . Furthermore, in a model of chronic volume and pressure overload using salt-sensitive Dahl rats fed a high-salt diet, riociguat significantly reduced glomerulosclerosis and interstitial and perivascular fibrosis, and significantly decreased mortality, compared with vehicle-treated rats [9] . In addition, riociguat in combination with telmisartan has been studied in a diabetic eNOS knockout mouse model, where animals were previously treated with an angiotensin II receptor blocker. Significant Vericiguat reduced mortality, improved systemic hypertension and tubulopathy, glomerulopathy, and vasculopathy in salt-sensitive rats fed a high-salt diet. In a low-NO/high-renin rat model of hypertension, vericiguat reduced right and left heart hypertrophy and mortality, and showed a positive effect on grading of kidney changes, and the incidence and severity of myocardial lesions Ang, angiotensin; cGMP, cyclic guanosine monophosphate; eNOS, endothelial nitric oxide synthase; HSFD, high-salt/high-fat diet; L-NAME, L-NGnitroarginine methyl ester; mRNA, messenger ribonucleic acid; NO, nitric oxide; PAI-1, plasminogen activator inhibitor-1; PBS, phosphate buffered saline; PDE, phosphodiesterase; sGC, soluble guanylate cyclase; TGFb, transforming growth factor beta. [36] ). Effects of the pharmacologic soluble guanylate cyclase stimulator BAY 41-2272 (10 mg/kg/day) in rats with induced anti-thy1 glomerulonephritis (GN). Blood pressure was measured in conscious animals using a tail cuff method. *P < 0.01 versus GN. (b) Example of effect on fibrosis (BAY 41-2272) (reproduced from [44] ). Area of fibrosis in rats treated with control, treated chronically with chronic N-nitro-L-arginine methyl ester (L-NAME; 20 mg/rat/day for eight weeks) alone or in association with BAY 41-2272 (10 mg/kg/day) or treated with BAY 41-2272 alone. Results are expressed as mean AE SEM. *P < 0.01 compared with control group, **P < 0.01 compared with L-NAME group. (c) Example of effect on survival (BAY 60-4552) (reproduced from [29] ). Survival following chronic administration of BAY 60-4552 (0.3 or 3.0 mg/kg/day) or GSK2181236A (0.1 or 1.0 mg/kg/day) in spontaneously hypertensive prone Sprague rats on a high-salt/high-fat diet (HFSD) versus rats on HFSD alone or no diet (ND). Results are expressed as mean AE SEM. *P < 0.001 versus HFSD. **P < 0.01 versus HFSD. ***P < 0.05 versus HFSD. (d) Example of effect on albumin reduction (riociguat) (reproduced from [35] ). Percentage reduction in urinary albumin excretion per day in diabetic, endothelial nitric oxide synthase knockout mice treated with riociguat (3 mg/ kg/day), telmisartan (1 mg/kg/day), and both (3 mg/kg/day and 1 mg/kg/day) compared with diabetic controls. Results are expressed as mean AE SEM. *P < 0.05 compared with diabetic vehicle. (e) Example of effect on creatinine clearance upon 5/6 nephrectomy (cinaciguat) (reproduced from [32] ). Change in creatinine clearance in male Wistar rats who were allocated to three groups: 5/6 nephrectomy, 5/6 nephrectomy treated with cinaciguat ($50 mg/day), and sham operation. Results are expressed as mean AE SD. *P < 0.001 versus sham operation. **P < 0.05 versus 5/6 nephrectomized rats.
reductions in urinary albumin excretion, an early sign of diabetic nephropathy, were observed compared with diabetic controls (Figure 2d ) [35] .
The combination of promising preclinical data and further positive clinical trials have led to the approval of riociguat (Adempas 1 ), making it the first of the sGC stimulators to be approved for clinical use in any indication [48] .
Vericiguat
Vericiguat (BAY 1021189), a more recent sGC stimulator, improved survival, systemic hypertension and tubulopathy, glomerulopathy, and vasculopathy in salt-sensitive
Renal effects of soluble guanylate cyclase stimulators and activators Stasch, Schlossmann and Hocher 101 Table 2 Summary of studies investigating sGC activators in experimental models of kidney and cardiovascular disease [22, 27, 29 In type-1 diabetic rats treated with cinaciguat the urinary protein:creatinine ratio was attenuated, and there was reduced glomerular sclerosis and tubular damage. Cinaciguat treatment also significantly decreased the elevated TGFb mRNA levels seen in the diabetic rats and the desmin expression of podocytes Chen et al.,
2014 [55] Cinaciguat
In a rat model of type-2 diabetic nephropathy (ZSF1), administration of cinaciguat in combination with an ACE-i resulted in a significant reduction in the incidence of glomerulosclerosis and tubulointerstitial lesions compared with vehicle, with benefits sustained beyond treatment discontinuation. Such an effect was not observed in the ACE-i + CCB group, demonstrating its dissociation from MAP lowering. Hoffmann et al.,
2014 [27] Cinaciguat High-salt diet only High-salt diet + cinaciguat
Long-term cinaciguat treatment of salt-sensitive rats on a high-salt diet resulted in significantly improved survival and reductions in blood pressure and heart rate compared with control animals. Urea and protein levels in urine and uric acid levels in plasma were also reduced with cinaciguat treatment. Dahl rats fed a high-salt diet (JP Stasch et al., unpublished). In a low-NO/high-renin rat model of hypertension, vericiguat reduced right and left ventricle hypertrophy and mortality, and showed a positive effect on grading of kidney changes, and the incidence and severity of myocardial lesions [49] [50] [51] [52] [53] 54 ]. The potentially beneficial effects of vericiguat on cardiac function are supported by the findings from recently completed phase I studies, which found that this agent leads to improvement in important cardiologic parameters, including: cardiac output/index, systemic vascular resistance, and stroke volume [49] . Clinical phase IIb trials are now underway in patients with heart failure who have reduced or preserved ejection fraction (SOCRATES, NCT01951625, and NCT01951638) [52] .
sGC activators
Effect of sGC activators in experimental kidney and cardiovascular disease
The effects of the sGC activators cinaciguat, ataciguat, BI 703704, and GSK2181236A have been investigated in experimental models of kidney and cardiovascular disease (Table 2) .
Cinaciguat (BAY 58-2667)
Several studies have demonstrated that cinaciguat has a protective renal effect. In rats with subtotal nephrectomy, chronic cinaciguat treatment lowered blood pressure, preserved renal function, improved plasma levels of natriuretic peptides, reduced left ventricular hypertrophy and cardiac arterial wall thickness, and slowed renal disease progression compared with untreated controls (Figure 2e ) [32] . Cinaciguat was further shown to inhibit podocyte damage, tubular damage, and glomerulosclerosis in a type-1 diabetic rat model of nephropathy [53] . In a rat model of type-2 diabetic nephropathy, administration of cinaciguat, together with the angiotensin-convertingenzyme inhibitor enalapril, resulted in significant and sustained reductions in glomerulosclerosis and tubulointerstitial lesions, compared with controls [55] . Under NO-deficient conditions, cinaciguat treatment of intact anesthetized rats at least partly stabilized the resultant hypertension and renal vasoconstriction, and re-established the modulation of renal blood flow autoregulation [22] . In a salt-sensitive rat hypertension model, long-term cinaciguat was associated with markedly improved survival, a lower increase in blood pressure, improvements in cardiac and renal function, and anti-fibrotic and anti-inflammatory effects compared with untreated controls [27] .
Ataciguat (HMR1766)
A new structural class of sGC activators includes the novel anthranilic acid derivative, ataciguat [37] . In a rat model of congestive heart failure, chronic treatment with ataciguat improved vascular function and sensitivity to NO, and reduced platelet activation [37] . In a rat model of non-inflammatory renal failure, ataciguat showed beneficial blood pressure-independent renoprotective effects on kidney structure and urinary albumin excretion compared with untreated controls [54 ] .
BI 703704
Recently presented but limited data showed BI 703704 to have a significant renal protective effect in a rat model of diabetic nephropathy when compared with untreated controls, with reductions in proteinuria and the incidence of glomerulosclerosis observed at doses that did not significantly alter blood pressure or heart rate [56] .
GSK2181236A
Limited published data suggest that GSK2181236A may provide partial benefit against hypertension-induced endorgan damage in rat models [29] .
Taken together, these results suggest that sGC activators also have the potential to provide pressure-independent renal and cardiac protection.
Discussion and conclusion
In in vivo experimental models of kidney and cardiovascular disease, the sGC stimulators BAY 41-2272, BAY 41-8543, BAY 60-4552, riociguat, and vericiguat have demonstrated protection against renal target organ damage in experimental CKD models (Table 1) . It is of note that this class of new drugs worked in the CKD models nearly independent of the underlying cause of CKD. We tested models of reduction of nephron numbers, malignant hypertension, immunological induced glomerulonephritis, and finally diabetic kidney disease were tested. Stimulation of sGC and subsequent cGMP production represents an important common pathway in the maintenance of renal function independent of the initial underlying cause of CKD, and therapeutic use of these sGC stimulators has been shown to produce a broad range of antifibrotic, antiproliferative, and antiproteinuric effects. It is of note that this new class of drugs can also improve blood pressure control at higher doses. This is of major clinical impact, since most patients with CKD suffer from hypertension which is an independent progression factor of CKD.
The results indicate that sGC stimulators may be capable of restoring physiological signaling in disorders where cGMP signaling has been disrupted. The sGC system has an important physiological role in both vascular and non-vascular tissues so the beneficial effects may extend to restoring the endothelium-mediated regulation of myocardial and renal function [51] . In addition, in in vivo models mirroring the pathophysiology of different subtypes of CKD and cardio-renal syndrome, the sGC activators cinaciguat, ataciguat, BI 703704, and GSK2181236A were capable of protecting and improving physiological renal function (Table 2 ).
In conclusion, preclinical data suggest that both sGC stimulators and sGC activators may offer therapeutic benefits for patients with CKD, on top of guideline-based renin-angiotensin system blockade. These novel drugs have the potential to address an unmet medical need in CKD, by providing an alternative for those patients in whom currently available guideline-recommended treatments alone are ineffective, and who are consequently at risk for rapid progression to ESRD. Clinical trials are required to confirm and extend these preclinical findings to humans.
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